Is N‑acetylcysteine an appropriate treatment for anxiety?

N-Acetylcysteine for Anxiety

N-acetylcysteine (NAC) is not FDA-approved for anxiety disorders and should not be used as a primary treatment, but emerging evidence suggests it may serve as a safe adjunctive therapy for anxiety symptoms, particularly in patients with comorbid conditions. 1

FDA-Approved Indications

• NAC is only FDA-approved for acetaminophen overdose to prevent hepatic injury, not for psychiatric conditions including anxiety disorders. 1
• The lack of regulatory approval for anxiety means this would constitute off-label use. 1

Evidence for Anxiolytic Effects

Preclinical Data

• Animal studies demonstrate consistent anxiolytic properties of NAC across multiple validated anxiety models (open field, light/dark, social interaction tests), with effects comparable to diazepam. 2
• NAC modulates glutamatergic, antioxidant, inflammatory, and neurotrophic pathways relevant to anxiety pathology. 2
• Subacute treatment (4 consecutive days) showed superior efficacy at lower doses compared to acute administration. 2

Clinical Evidence in Humans

• In patients with multiple sclerosis, NAC 600 mg twice daily for 8 weeks significantly reduced anxiety scores (HADS-A) compared to placebo, while also decreasing oxidative stress markers. 3
• NAC reversed chemotherapy-induced anxiety-like behaviors in multiple studies, suggesting efficacy in anxiety secondary to medical treatments. 4, 5
• A 2025 comprehensive review indicates NAC shows promise for anxiety disorders through oxidative stress reduction and glutamatergic modulation, though clinical evidence remains limited. 6

Mechanisms of Action

• NAC acts as a glutathione precursor and antioxidant, reducing oxidative stress implicated in anxiety pathophysiology. 3, 6
• It normalizes HPA axis hyperactivity and reduces plasma corticosterone levels associated with anxiety states. 7
• NAC modulates glutamatergic neurotransmission and increases brain-derived neurotrophic factor (BDNF) release in anxiety-relevant brain regions. 4, 6

Clinical Considerations

Dosing

• Effective doses in clinical studies range from 1000-3000 mg daily, most commonly 1200 mg daily (600 mg twice daily). 3, 6
• Treatment duration of 8-24 weeks appears necessary for therapeutic effects. 6, 8

Safety Profile

• NAC has a favorable safety profile with minimal adverse effects, making it advantageous over benzodiazepines for long-term use. 2
• The only contraindication is hypersensitivity to acetylcysteine. 1

Role in Treatment Algorithm

• NAC should be considered as adjunctive therapy only, not as monotherapy for primary anxiety disorders. 6
• It may be particularly useful in anxiety comorbid with depression, bipolar disorder, or medical conditions where oxidative stress plays a role. 7, 3, 6
• Standard first-line treatments (SSRIs, SNRIs, CBT) remain the primary approach for anxiety disorders. 9

Important Caveats

• The evidence base consists primarily of animal studies and small clinical trials in specific populations (MS patients, chemotherapy recipients), not generalized anxiety disorder. 3, 4, 5
• Large-scale randomized controlled trials specifically for primary anxiety disorders are lacking. 6
• NAC shows more robust evidence for depression than anxiety, with mixed results across psychiatric conditions. 8